UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant to Rule 13A-16
or 15d-16 of
The
Securities Exchange Act of 1934
For
the month of April 2018
COMMISSION
FILE Number.
000-29338
CARDIOME
PHARMA CORP.
(Translation
of registrant’s name into English)
1441
Creekside Drive, 6th floor
Vancouver,
British Columbia, V6J 4S7, CANADA
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS REPORT
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
| |
CARDIOME
PHARMA CORP. |
| |
(Registrant) |
| |
|
|
| Date: April 17, 2018 |
By: |
/s/
Justin Renz |
| |
|
Name: Justin Renz |
| |
|
Title: Chief Financial Officer |
Exhibit 99.1
Cardiome Completes Enrollment in the Post Approval Safety
Study SPECTRUM Evaluating Brinavess®
NASDAQ: CRME TSX: COM
VANCOUVER, April 17, 2018 /CNW/ - Cardiome Pharma Corp.
(NASDAQ: CRME / TSX: COM), a revenue-generating, specialty pharmaceutical company focused on commercializing hospital drugs, today
announced completion of enrollment for the Phase 4 SPECTRUM study evaluating Brinavess® (vernakalant hydrochloride,
IV), the Company's antiarrhythmic drug for the rapid conversion of recent onset atrial fibrillation (AF), in the post-authorization
setting in the European Union (EU).
In this prospective and retrospective observational registry,
2,000 patients were enrolled and assessed to characterize normal conditions of use, dosing and safety following administration
of Brinavess. The full clinical study report (CSR) will be available during third quarter 2018 and Cardiome plans to publish
these data.
"Completion of enrollment in the SPECTRUM study is an
important event for Brinavess as this large clinical study fulfills our clinical commitments in the EU and adds important data
on the use of Brinavess in the real-world setting," said Kiran Bhirangi, M.D., Cardiome's Vice President, Clinical Development
and Medical Affairs. "This observational registry is designed to provide robust, supportive data on the safety and effectiveness
of Brinavess and how it is used in real-world clinical practice. We believe Brinavess is an important treatment alternative
for patients with recent onset AF, particularly for those who require pharmacologic cardioversion. Brinavess has been demonstrated
to rapidly induce cardioversion and it remains a clinically proven option for physicians treating patients in the acute hospital
setting."
About Atrial Fibrillation
Atrial Fibrillation (also known as AFib or AF) is a supraventricular
tachyarrhythmia with uncoordinated atrial activation resulting in ineffective atrial contraction and, if left untreated, structural
and/or electrophysiological atrial tissue abnormalities.1 AF is a common cardiac rhythm disturbance that increases in
prevalence with advancing age.1 According to the American Heart Association, estimates of the prevalence of AF in the
U.S. ranged from 2.7 million to 6.1 million in 2010, and is expected to rise to between 5.6 million to 12 million in 2030.2
There are two strategies to manage AF, namely, rhythm- or rate-control. A rhythm-control strategy may be used in patients who are
severely compromised, remain symptomatic despite adequate rate control, when adequate rate control is difficult to achieve, when
long term rhythm control therapy is preferred, younger patient age, presence of tachycardia-mediated cardiomyopathy, and first
episode of AF.1,3 Early intervention with a rhythm-control strategy to prevent progression of AF may be particularly
beneficial to the AF patient.1
About BRINAVESS®
Brinavess® (vernakalant HCl, IV) is an antiarrhythmic
drug that acts preferentially in the atria by prolonging atrial refractoriness and slowing impulse conduction in a rate-dependent
fashion. Brinavess is approved for marketing in Europe, Canada and several other countries worldwide. In Europe, it is approved
for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults: 1) for non-surgery patients: atrial fibrillation
< 7 days duration; and 2) for post-cardiac surgery patients: atrial fibrillation < 3 days duration. Vernakalant IV is not
approved for use in the United States.
About Cardiome Pharma Corp.
Cardiome Pharma Corp. is a revenue-generating, specialty pharmaceutical
company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a
commercial presence and distribution network covering over 60 countries worldwide, Cardiome develops, acquires and commercializes
brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™
(dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio®
(ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia
(CAP, HAP); Brinavess® (vernakalant IV), for the rapid conversion of recent onset atrial fibrillation to sinus rhythm;
Aggrastat® (tirofiban hydrochloride), for the reduction of thrombotic cardiovascular events in patients with acute
coronary syndrome, and Esmocard® and Esmocard Lyo® (esmolol hydrochloride), a short-acting beta-blocker
used to control rapid heart rate in a number of cardiovascular indications. Cardiome's pipeline of product candidates includes
Trevyent®, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for
pulmonary arterial hypertension.
Cardiome is traded on the NASDAQ Capital Market (CRME) and
the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.
References
| 1. | January CT et al. 2014 AHA/ACC /HRS guideline for
the management of patients with atrial fibrillation. J AM Coll Cardiol. 2014;34:e1-e76. |
| 2. | Mozaffarian D et al. Heart Disease and Stroke Statistics-2016
Update: A Report From the American Heart Association. Circulation. 2016 Jan 26;133(4):e38-60. |
| 3. | Camm AJ et al. Guidelines for the management of atrial
fibrillation, The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J.
2010;31:2369-2429. |
Forward-Looking Statement Disclaimer
Certain statements in this news release contain forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 or forward-looking information under
applicable Canadian securities legislation ("forward-looking statements") that may not be based on historical fact, including
without limitation statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments
to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
A discussion of the risks and uncertainties facing Cardiome are discussed in our most recent annual and quarterly reports and detailed
from time to time in our other filings with the Securities and Exchange Commission ("SEC") available at www.sec.gov and
the Canadian securities regulatory authorities at www.sedar.com. All of the risks and certainties disclosed in these filings are
hereby incorporated by reference in their entirety. While Cardiome makes these forward-looking statements in good faith, given
these risks, uncertainties and factors, you are cautioned not to place undue reliance on any forward-looking statements made in
this press release. All forward-looking statements made herein are based on our current expectations and we undertake no obligation
to revise or update such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Cardiome® and the Cardiome Logo are the proprietary
trademarks of Cardiome Pharma Corp.
Aggrastat® and Brinavess® are trademarks owned by Cardiome and its affiliates worldwide.
Xydalba® is a trademark of Durata Therapeutics Holding C.V., and used under license.
Zevtera® and Mabelio® are trademarks owned by Basilea Pharmaceutica International Ltd., and used
under license.
Esmocard® and Esmocard Lyo® are trademarks owned by Orpha-Devel Handels und Vertriebs GmbH, and used
under license.
Trevyent® is a trademark of SteadyMed and used under license.
All other trademarks are the property of their respective owners.
View
original content:http://www.prnewswire.com/news-releases/cardiome-completes-enrollment-in-the-post-approval-safety-study-spectrum-evaluating-brinavess-300630538.html
SOURCE Cardiome Pharma Corp.
View original content: http://www.newswire.ca/en/releases/archive/April2018/17/c1922.html
%CIK: 0001036141
For further information: Justin Renz, CFO, Cardiome Pharma
Corp., 604.677.6905 ext. 128, 800.330.9928, jrenz@cardiome.com; Argot Partners, Michelle Carroll, 212.600.1902, michelle@argotpartners.com
CO: Cardiome Pharma Corp.
CNW 08:00e 17-APR-18
This regulatory filing also includes additional resources:
ex991.pdf
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Correvio Pharma (NASDAQ:CORV)
Historical Stock Chart
From Apr 2023 to Apr 2024
